PET Scans Inform, Improve Treatment in Esophageal Cancer
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.
Among patients with advanced colorectal cancer, greater total physical activity improved progression-free and overall survival.
Despite differences in the safety profiles and rates of adverse events, both FOLFIRI and XELIRI were safe and well-tolerated as second-line therapy.
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Treatment with nintedanib significantly improved progression-free survival among heavily pretreated patients with metastatic colorectal cancer (mCRC).
Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations (CRGA) that could lead to targeted drug therapy.
Endothelial nitric oxide synthase (eNOS) VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,
Baseline α-fetoprotein (AFP) levels may be a predictive marker for advanced hepatocellular carcinoma receiving ramucirumab.
Comprehensive genomic profiling (CGP) shows promise in advanced esophageal squamous cell carcinomas (ESCC) and adenocarcinoma (EAC).